Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase

Jian  Chang; Zhang Yu-tong; FENG Li-hua; Zhong  Xiao-dan; Wang Li-zhe

IJ Pediatrics

The Scientific Journal of Growth & Development Research Center

Outlines

Abstract
References
Copyright

Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase

Author(s):

Jian Chang^1,*,

Zhang Yu-tong²,

FENG Li-hua³,

Zhong Xiao-dan⁴,

Wang Li-zhe⁵

IJ Pediatrics:Vol. 24, issue 1; 75-80

Published online:Jan 26, 2014

Article type:Research Article

Received:Apr 06, 2013

Accepted:Dec 08, 2013

How to Cite:Jian ChangZhang Yu-tongFENG Li-huaZhong Xiao-danWang Li-zheTreatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase.Iran J Pediatr.24(1):75-80.

Abstract

Objective: To evaluate the feasibility of Pegaspargase instead of L-asparaginase to treat children with advanced-stage lymphoblastic lymphoma (LBL) on the Berlin-Frankfurt-Munster (BFM)-95 protocol. Methods: Fifty-four newly diagnosed patients with stage III or IV LBL and without any treatment were enrolled in this study. Pegaspargase took place of L-asparaginase in BFM-95. The complications and treatment responses of patients treated on the BFM-95 protocol and modified BFM-95 protocol were then evaluated respectively. Findings: For LBL patients treated with BFM-95 protocol or modified BFM-95 protocol, the complete response, event-free survival, overall survival were similar. Stage 4 myelosuppression was the most common complication in both groups. Besides that, among 31 patients receiving modified BFM-95 protocol, coagulation defects were the most common complication. In contrast, anaphylactic reaction was the most common complication in the other 23 patients receiving BFM-95 protocol. Conclusion: Modified BFM-95 protocol is available to children with advanced-stage LBL with an equal outcome and enhances its compliance and decreases the incidence of anaphylactic reaction, compared to BFM-95 protocol. Coagulation defects are the major complication and tolerable in modified one.

Keywords

Pegaspargase

L-Asparaginase

Lymphoblastic Lymphoma

Chemotherapy

Fulltext

Click here to download PDF.

References

comments